Embla Medical hf
26.33
DKK
+0.53
(+2.05%)
Embla Medical hf
LSE:0FIW
(London Stock Exchange)
Recent
price
26.33
P/E
ratio
19.79
div
yld
- -
ROIC.AI
Capital Structure
USD
•
in mil. unless spec.Working Capital
USD
•
in mil. unless spec.Growth Rates
USD
•
in mil. unless spec.Quarterly Revenue
USD
•
in mil. unless spec.Quarterly Earnings Per Share
USD
•
in mil. unless spec.Quarterly Dividends Per Share
USD
•
in mil. unless spec.- Similar Companies
- Business
- Embla Medical hf. engages in the design, manufacture, and distribution of non-invasive orthopedic products and related patient care services. The company focuses on prosthetics and neuro-orthotics, bracing and supports, and patient care solutions, delivering an end-to-end ecosystem from product development to clinical delivery. Its products include lower- and upper-limb prosthetics, microprocessor-controlled and bionic components, neuro-orthotic joints, and a range of spinal, hip, knee, foot, ankle, and hand braces and supports; it also operates orthotic and prosthetic clinics and patient care networks to support rehabilitation and functional outcomes. Founding year and headquarters - Founded in 2005, Embla Medical hf is headquartered in Reykjavik, Iceland, with operations expanding across Europe, the Middle East, Africa, the Americas, and the Asia-Pacific region through its member brands and subsidiaries. Core business model and structure - Core segments include Prosthetics and Neuro Orthotics (mechanical and advanced electronic components for limb loss and differences, including microprocessor-controlled devices and neuro-orthotic solutions), Bracing and Supports (spinal, hip, knee, foot, ankle, and hand devices; injury recovery and post-operative supports), and Patient Care (prosthetics and orthotics services delivered through clinics and networks). Latest major company changes - In the past two years, Embla Medical hf advances Growth'27 through strategic acquisitions and market expansion, most notably acquiring a majority stake in Streifender ortho.production to broaden its full-range offerings, strengthen geographic reach, and enhance service delivery in key markets. - The company continues to report progress on its strategic initiatives, including organic growth and selective acquisitions to augment portfolio breadth and clinical delivery capabilities, as highlighted in its 2025 annual results and Growth'27 framework. Geographic footprint and markets - Operates across Europe, the Middle East, Africa, the Americas, and the Asia-Pacific, serving hospitals, clinics, orthotics and prosthetics retailers, and direct care networks; targets clinicians and patients requiring prosthetic, neuro-orthotic, bracing, and rehabilitation solutions. Subsidiaries and relationships - Embla Medical hf operates through a network of brands and subsidiaries aligned under its end-to-end platform, incorporating established orthotics and prosthetics brands and clinics to deliver integrated products and patient care services; the parent structure emphasizes cohesive product development and clinic-based care pathways. Customer focus and value proposition - Serves healthcare providers and patients requiring advanced prosthetic and orthotic solutions, with emphasis on improving mobility, gait, and functional outcomes through integrated devices, clinical delivery, and postoperative rehabilitation support. The company positions itself as a full-range provider from device innovation to patient care services, aiming for scalable growth through geographic expansion and strategic investments.
Company News
Embla Medical hf. (OSSUY) Q3 2026 Earnings Call Transcript
Embla Medical hf. (OSSUY) Q2 2026 Earnings Call Transcript
Embla Medical hf. (OSSUY) Q1 2026 Earnings Call Transcript
Embla Medical hf. (OSSUY) Q4 2025 Earnings Call Transcript
Embla Medical hf. (OSSUY) Q3 2025 Earnings Call Transcript
Embla Medical hf: Embla Medical signs agreement to invest in a majority share in Streifeneder ortho.production GmbH